Watch CBS News

Tuesday Is Last Day To Get 1st Dose Of Pfizer COVID-19 Vaccine At Pennsylvania Convention Center

PHILADELPHIA (CBS) -- Big changes are coming to Philadelphia's largest COVID-19 vaccination site.
Today is the last day you can walk into the FEMA-run clinic at the Pennsylvania Convention Center to get your first dose of the Pfizer vaccine.

It's the last call for people to get their first dose of the Pfizer vaccine at the Pennsylvania Convention Center at 12th and Arch Streets.

"Philly's done a really good job of rolling it. I made an appointment last night," Jeff Reinhart said. "Normalcy. Hopefully, get back out for the summer and fall. That's pretty much where my head's at now."

"We hope to have vaccinated as many Philadelphians as possible," said Charlie Elison with FEMA.

Officials with this FEMA-run vaccination clinic are giving a final friendly reminder to those who want to be vaccinated that time is running out. The last walk-ins are being accepted until 5 p.m. this evening.

"It's a busy day here but at the same time, we still have a lot of walk-up opportunities for folks who want to come out and get their Pfizer dose one. You come here you get your Pfizer dose one. Three weeks later you get your Pfizer dose two," Elison said.

"Take the plunge. It's worth it for some normalcy," Reinhart said.

"Just come on out. If you're concerned about the long line or the long wait, there is near a zero wait here. If you're concerned about standing up for a long time we've got wheelchairs, we've got a host of access and functional needs capabilities, and if you're concerned we don't speak your language we've got a dozen interpreters in several different languages standing by inside ready to help. We will make it as easy as possible to get your vaccine," Elison said.

The FEMA-run sites will continue to be around for a little while longer as they distribute second doses.

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.